All about PSY DREAM. Psychiatric Drug Registration, Evaluation & All-Inclusive Monitoring.
OBJECTIVE
In this article the author--board-member of the European Network of (ex-) Users and Survivors of Psychiatry (ENUSP)--explains, what is needed to guarantee a minimal level of involvement of users and survivors of psychiatry into issues relating to psychiatric drugs.


METHODS
He reflects demands of their organisations, and compares these demands with the current involvement level. Considering the concrete circumstances in psychiatry, he reflects the risks and dangers of the administered drugs--especially the widely used neuroleptics--for example enhanced breast cancer risk in women, suicidal effects, receptor changes, tardive dyskinesia and other toxic reactions.


RESULTS
Considering the unique situation of psychiatric patients to receive treatment in general without informed consent and in a violent way or through bullying and threat, he argues for to provide their involvement in all aspects of psychiatric drug issues--especially registration and monitoring, for example by their involvement in creating and running a suicide register. And he argues for involvement in ethics committees, licensing processes and providing guidelines and decision making about effectiveness and reimbursement of costs.


CONCLUSIONS
As first steps towards these aims he proposes independent and user-controlled research, independent and user-controlled education and independent and user-controlled information about the effects of psychiatric drugs.
Lehmann
Peter
P
info@peter-lehmann.de
D003256:Community Participation; D016903:Drug Monitoring; D006304:Health Status; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D008605:Mental Health Services; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D000078329:Workforce
D011619:Psychotropic Drugs